Gasherbrum Bio, Inc., A Wholly Owned Subsidiary Of Structure Therapeutics

This study is testing whether an investigational drug called aleniglipron can change body composition—specifically reducing fat mass while preserving muscle—in adults living with obesity. About 71 participants will receive either the drug or a placebo for 40 weeks. The main goal …

This study is testing whether a new medication called aleniglipron (GSBR-1290) can help adults with obesity or overweight lose weight when combined with diet and exercise. Researchers will compare the drug against a placebo in 82 participants over 44 weeks to see if it's safe and…

This study is testing whether an experimental medication called aleniglipron helps people with obesity or overweight lose weight. About 220 participants will receive either the drug or a placebo for 36 weeks, with an option to continue for another 36 weeks. The main goal is to se…